Compare Rion Co., Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 13.14% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 6.19% and Operating profit at 13.14% over the last 5 years
3
Flat results in Jun 26
4
With ROE of 9.11%, it has a very attractive valuation with a 1.38 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 42,044 Million (Small Cap)
15.00
NA
0.00%
-0.25
9.61%
1.21
Revenue and Profits:
Net Sales:
6,885 Million
(Quarterly Results - Jun 2026)
Net Profit:
688 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.56%
0%
-4.56%
6 Months
22.6%
0%
22.6%
1 Year
28.97%
0%
28.97%
2 Years
66.83%
0%
66.83%
3 Years
57.39%
0%
57.39%
4 Years
66.27%
0%
66.27%
5 Years
31.58%
0%
31.58%
Rion Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.19%
EBIT Growth (5y)
13.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.88
Tax Ratio
23.50%
Dividend Payout Ratio
31.32%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
15.58%
ROE (avg)
8.50%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.38
EV to EBIT
9.37
EV to EBITDA
6.99
EV to Capital Employed
1.50
EV to Sales
1.35
PEG Ratio
2.32
Dividend Yield
NA
ROCE (Latest)
15.98%
ROE (Latest)
9.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
6,885.40
6,629.10
3.87%
Operating Profit (PBDIT) excl Other Income
1,313.00
1,151.20
14.05%
Interest
0.80
0.80
Exceptional Items
0.00
0.00
Consolidate Net Profit
687.90
595.10
15.59%
Operating Profit Margin (Excl OI)
143.60%
125.20%
1.84%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 3.87% vs 4.31% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 15.59% vs 48.48% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
28,502.00
27,877.90
2.24%
Operating Profit (PBDIT) excl Other Income
5,765.80
5,276.40
9.28%
Interest
2.30
2.20
4.55%
Exceptional Items
0.00
-164.70
100.00%
Consolidate Net Profit
3,345.60
2,859.80
16.99%
Operating Profit Margin (Excl OI)
153.00%
144.70%
0.83%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 2.24% vs 8.36% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 16.99% vs 7.82% in Mar 2025
About Rion Co., Ltd. 
Rion Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






